We are a gene therapy startup located  @MaRS Toronto

 

 
 
 
Screen Shot 2017-08-28 at 7.18.20 PM.png

Our
Mission

 

Mediphage Bioceuticals Acts Locally to Make a Global Impact.

We are committed to developing gene therapy platforms that enable the development of in-need therapeutics. We act with integrity, honesty, and are committed to bettering mankind in a safe and efficacious way. We form partnerships with leading pharmaceutical companies and thought leaders to enable a global impact. 

Inception.

December, 2015

Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.

Seed Round.

March, 2016

Mediphage Bioceuticals closes its seed round of 490K to develop proof of concept and perform early stage efficacy studies.

Concept Testing.

February, 2017

Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.

MARS Toronto.

March, 2017

Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.

Our
Journey

 

Screen Shot 2017-08-28 at 8.52.21 PM.png

Our Platforms

 
 

DNA Ministrings

One to two sentences summarizing what DNA ministrings are and their purpose. i.e. its the modifiable/ customizable therapeutic

 

iPhage

One to two sentences summarizing what iPhages are and what their purpose is. i.e. its the targeted delivery system for the DNA ministring therapeutic

 

Management Team

 
roderick.png

Dr. Roderick Slavcev

Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol

 

Shirley Wong Headshot.png

Shirley Wong

Senior Scientist

jonathan.png

Dr. Jonathan Blay

CSO, PhD, FIBMS, FRSB, CSci, CBiol

Vanessa Ferlaino Headshot_formatted.png

Vanessa Ferlaino

Chief Operating Officer

Lee_Bowman300x300.png

Lee Bowman

Director of Advancement


Advisory Board

grant.png

Dr. Grant Isaac

CFO, Cameco

sanjay.png

Dr. Sanjay Singh

President & CEO, Temple Therapeutics, Director, BioteCanada

michael.png

Dr. Michael Naso

Director R&D, Johnson & Johnson

 

jake.png

Dr. Jake Thiessen

Founder, University of Waterloo, School of Pharmacy (retired)

Screen Shot 2018-01-23 at 10.16.29 AM.png